As reported by Law360 (subscription), Allergan has agreed to pay $30 million to settle an antitrust lawsuit filed by Lieff Cabraser and co-counsel on behalf of a group of pharmaceutical purchasers, union benefit plans, and other buyers of Allergan’s blockbuster dry-eye disease drug Restasis. The sweeping litigation accused the drugmaker of misconduct intended to illegally limit competition from generic drugs to the detriment of patients and their healthcare plans.
According to the filing, after nearly four years of hard-fought litigation, the parties agreed that the settlement provided an optimal outcome.
“Continuing to litigate would considerably delay relief and impose substantial costs, which weighs in favor of preliminary approval,” the end payor plaintiffs said. With the settlement, “the class will obtain immediate relief and avoid the potential risks and delay of trial and appeal.”
Read the full article on Law360’s (subscription) website.
Learn more about the Restasis antitrust litigation.